Next Article in Journal / Special Issue
Gut Microbiota and Iron: The Crucial Actors in Health and Disease
Previous Article in Journal / Special Issue
How Eliminating Malaria May Also Prevent Iron Deficiency in African Children
Review

Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation

1
Department of Internal Medicine, University Hospital Virgen de la Victoria. Campus de Teatinos, 2010 Málaga, Spain
2
Scientific Department, Alesco S.r.l. Via delle Lenze, 216/B, 56122 Pisa, Italy
3
Scientific Department, Pharmanutra S.p.A. Via delle Lenze, 216/B, 56122 Pisa, Italy
4
Perioperative Transfusion Medicine, Department of Surgical Specialties, Biochemistry and Immunology, School of Medicine, Campus de Teatinos, 29071 Málaga, Spain
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2018, 11(4), 97; https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040097
Received: 30 August 2018 / Revised: 28 September 2018 / Accepted: 2 October 2018 / Published: 4 October 2018
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases)
Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced compliance with treatment. Intravenous (IV) iron formulations are increasingly safe, but there is still a risk of infusion, hypersensitivity reactions and the need for venous access and infusion monitoring. Sucrosomial® Iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells). This confers SI’s unique structural, physicochemical and pharmacokinetic characteristics, together with its high iron bioavailability and excellent gastrointestinal tolerance. The analysis of the available evidence supports oral SI iron as a valid option for ID treatment, which is more efficacious and tolerable than oral iron salts. SI has also demonstrated a similar effectiveness, with lower risks, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery). Thus, oral SI emerges as a valuable first option for treating ID, especially for subjects with intolerance to iron salts or those for whom iron salts are inefficacious. Moreover, SI should also be considered as an alternative to IV iron for initial and/or maintenance treatment in different patient populations. View Full-Text
Keywords: Anemia; iron deficiency; oral iron salts; intravenous iron; Sucrosomial® iron; M cells; bioavailability; tolerability; efficacy Anemia; iron deficiency; oral iron salts; intravenous iron; Sucrosomial® iron; M cells; bioavailability; tolerability; efficacy
Show Figures

Figure 1

MDPI and ACS Style

Gómez-Ramírez, S.; Brilli, E.; Tarantino, G.; Muñoz, M. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals 2018, 11, 97. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040097

AMA Style

Gómez-Ramírez S, Brilli E, Tarantino G, Muñoz M. Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals. 2018; 11(4):97. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040097

Chicago/Turabian Style

Gómez-Ramírez, Susana, Elisa Brilli, Germano Tarantino, and Manuel Muñoz. 2018. "Sucrosomial® Iron: A New Generation Iron for Improving Oral Supplementation" Pharmaceuticals 11, no. 4: 97. https://0-doi-org.brum.beds.ac.uk/10.3390/ph11040097

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop